Trial Profile

Phase I clinical trial assessing FIB918

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FIB 918 (Primary)
Indications Hereditary nephritis
Focus Adverse reactions

Most Recent Events

12 Mar 2024 New trial record
05 Mar 2024 According to Fibrocor Therapeutics media release , Fibrocor Therapeutics entered into a research and development collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome program. FIB918 is now in the IND-enabling phase and Phase 1 clinical trials of the monoclonal antibody are targeted to start in late 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com